Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.32 | 0.18 | -0.03 | 0.22 |
| FCF Yield | -4.53% | -9.15% | -35.60% | -14.79% |
| EV / EBITDA | -9.15 | -8.84 | -1.15 | -9.58 |
| Quality | ||||
| ROIC | -32.06% | -24.07% | -82.51% | -62.43% |
| Gross Margin | 82.61% | 86.54% | 88.41% | 92.80% |
| Cash Conversion Ratio | 0.53 | 1.27 | 0.79 | 1.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.34% | 34.45% | 46.52% | – |
| Free Cash Flow Growth | 42.30% | 64.13% | 26.66% | -13.26% |
| Safety | ||||
| Net Debt / EBITDA | 2.17 | 3.10 | 1.10 | 3.27 |
| Interest Coverage | 0.00 | 0.00 | -125.25 | -62.33 |
| Efficiency | ||||
| Inventory Turnover | 2.11 | 2.25 | 1.13 | 0.46 |
| Cash Conversion Cycle | 95.16 | 64.81 | -290.39 | -1,086.64 |